造血细胞移植后预防移植物抗宿主病的方法。
Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.
作者信息
Gatza Erin, Choi Sung Won
机构信息
Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, United States; Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, MI, United States.
出版信息
Int J Hematol Oncol. 2015 Aug;4(3):113-126. doi: 10.2217/ijh.15.13.
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for malignant and non-malignant diseases, but the more widespread application of the therapy remains limited by the occurrence of graft versus host disease (GVHD). GVHD results from immune-mediated injury by donor immune cells against tissues in the HCT recipient, and can be characterized as acute or chronic depending on the time of onset and site of organ involvement. The majority of efforts have focused on GVHD prevention. Calcineurin inhibitors are the most widely used agents and are included in almost all regimens. Despite current prophylaxis strategies, 40-70% of patients remain at risk for developing GVHD. Herein, we review standard and emerging therapies used in GVHD management.
摘要
异基因造血细胞移植（HCT）是治疗恶性和非恶性疾病的重要选择，但该疗法更广泛的应用仍受到移植物抗宿主病（GVHD）发生的限制。GVHD是由供体免疫细胞对HCT受者组织的免疫介导损伤引起的，根据发病时间和器官受累部位可分为急性或慢性。大多数努力都集中在预防GVHD上。钙调神经磷酸酶抑制剂是使用最广泛的药物，几乎所有方案中都包含。尽管有目前的预防策略，40%-70%的患者仍有发生GVHD的风险。在此，我们综述了用于GVHD管理的标准疗法和新兴疗法。
相似文献
1
Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation.
Int J Hematol Oncol. 2015 Aug;4(3):113-126. doi: 10.2217/ijh.15.13.
2
3
Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15.
4
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Biol Blood Marrow Transplant. 2019 Jan;25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018 Aug 25.
5
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6.
6
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Biol Blood Marrow Transplant. 2014 Nov;20(11):1828-34. doi: 10.1016/j.bbmt.2014.07.020. Epub 2014 Jul 23.
7
Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Expert Opin Investig Drugs. 2016 Aug;25(8):957-72. doi: 10.1080/13543784.2016.1182498. Epub 2016 May 9.
8
Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.
Rev Recent Clin Trials. 2008 May;3(2):130-8. doi: 10.2174/157488708784223790.
9
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302. doi: 10.1016/j.bbmt.2017.04.009. Epub 2017 Apr 12.
10
Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
Med Arh. 2011;65(5):260-4. doi: 10.5455/medarh.2011.65.260-264.
引用本文的文献
1
Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.
Pharmaceuticals (Basel). 2022 Sep 3;15(9):1100. doi: 10.3390/ph15091100.
2
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.
Int J Mol Sci. 2020 Jun 16;21(12):4281. doi: 10.3390/ijms21124281.
3
Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.
Br J Haematol. 2021 Mar;192(6):951-967. doi: 10.1111/bjh.16497. Epub 2020 Feb 10.
4
Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.
Transfusion. 2020 Jan;60(1):144-154. doi: 10.1111/trf.15592. Epub 2019 Nov 22.
5
Targeting of CD133+ Cancer Stem Cells by Mesenchymal Stem Cell Expressing TRAIL Reveals a Prospective Role of Apoptotic Gene Regulation in Non-Small Cell Lung Cancer.
Cancers (Basel). 2019 Aug 28;11(9):1261. doi: 10.3390/cancers11091261.
6
Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.
Curr Pathobiol Rep. 2018;6(4):247-263. doi: 10.1007/s40139-018-0186-6. Epub 2018 Nov 19.
7
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Biol Blood Marrow Transplant. 2018 Nov;24(11):2324-2336. doi: 10.1016/j.bbmt.2018.04.021. Epub 2018 Apr 21.
8
Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?
Int J Mol Sci. 2017 May 9;18(5):1022. doi: 10.3390/ijms18051022.
9
Herpesvirus Entry Mediator and Ocular Herpesvirus Infection: More than Meets the Eye.
J Virol. 2017 Jun 9;91(13). doi: 10.1128/JVI.00115-17. Print 2017 Jul 1.
本文引用的文献
1
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
Lancet Haematol. 2015 Jan;2(1):e21-9. doi: 10.1016/S2352-3026(14)00035-0. Epub 2014 Dec 23.
2
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.
Biol Blood Marrow Transplant. 2015 Jul;21(7):1167-87. doi: 10.1016/j.bbmt.2015.03.024. Epub 2015 Mar 31.
3
Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Biol Blood Marrow Transplant. 2015 Jul;21(7):1315-20. doi: 10.1016/j.bbmt.2015.02.008. Epub 2015 Mar 9.
4
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7.
5
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Biol Blood Marrow Transplant. 2015 May;21(5):780-92. doi: 10.1016/j.bbmt.2015.01.003. Epub 2015 Jan 30.
6
Grading acute graft-versus-host disease: time to reconsider.
Pediatr Transplant. 2015 May;19(3):252-4. doi: 10.1111/petr.12433. Epub 2015 Jan 20.
7
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.
8
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.
9
Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
Lancet Oncol. 2014 Dec;15(13):1451-1459. doi: 10.1016/S1470-2045(14)71017-4. Epub 2014 Nov 14.
10
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
Blood. 2015 Jan 29;125(5):815-9. doi: 10.1182/blood-2014-10-605238. Epub 2014 Nov 26.
Zotero 插件